Amneal Pharmaceuticals (AMRX) Cash from Investing Activities (2017 - 2026)

Amneal Pharmaceuticals' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$21.7 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 21.98% year-over-year to -$21.7 million in Q1 2026; TTM through Mar 2026 was -$116.2 million, a 90.34% decrease from a year earlier, with the FY2025 full-year figure at -$112.3 million, down 78.21% from the prior year.
• Cash from Investing Activities improved to -$21.7 million in Q1 2026 per AMRX's latest filing, from -$45.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at -$6.5 million in Q2 2024 and bottomed at -$97.4 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is -$19.8 million (2024), against an average of -$25.9 million.
• Across the five-year window, Cash from Investing Activities slumped 667.31% in 2022 and soared 87.95% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$11.5 million in 2022, then sank by 176.4% to -$31.7 million in 2023, then soared by 49.33% to -$16.1 million in 2024, then plunged by 183.04% to -$45.5 million in 2025, then surged by 52.24% to -$21.7 million in 2026.
• Per Business Quant, the three latest AMRX Cash from Investing Activities figures stand at -$21.7 million (Q1 2026), -$45.5 million (Q4 2025), and -$22.5 million (Q3 2025).